Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2016 | Pages:
72 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline Review, H1 2016', provides an overview of the Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - The report reviews pipeline therapeutics for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) therapeutics and enlists all their major and minor projects - The report assesses Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Overview 7 Therapeutics Development 8 Pipeline Products for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Overview 8 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Therapeutics under Development by Companies 9 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Products under Development by Companies 13 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Companies Involved in Therapeutics Development 14 Biscayne Pharmaceuticals, Inc. 14 GW Pharmaceuticals Plc 15 INSYS Therapeutics, Inc. 16 OPKO Health, Inc. 17 PTC Therapeutics, Inc. 18 Sage Therapeutics, Inc. 19 Xenon Pharmaceuticals Inc. 20 Zogenix, Inc. 21 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Therapeutics Assessment 22 Assessment by Monotherapy Products 22 Assessment by Target 23 Assessment by Mechanism of Action 25 Assessment by Route of Administration 27 Assessment by Molecule Type 29 Drug Profiles 31 ataluren - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 BIS-001 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 cannabidiol - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 cannabidiol - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 CUR-1916 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 fenfluramine hydrochloride - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Oligonucleotide for Dravet Syndrome - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 SAGE-217 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Small Molecule to Block Nav1.6 for Dravet Syndrome - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Recent Pipeline Updates 46 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Dormant Projects 60 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Product Development Milestones 61 Featured News & Press Releases 61 May 05, 2016: Zogenix Announces ZX008 New Efficacy and Safety Data for Treatment of Seizures in Dravet Syndrome 61 Apr 21, 2016: New Data on Zogenix ZX008 for Dravet Syndrome to be Presented at 14th International Child Neurology Congress 62 Mar 14, 2016: GW Pharmaceuticals Announces Positive Phase 3 Pivotal Study Results for Epidiolex (cannabidiol) 62 Feb 25, 2016: Edison Issues ADR Update on GW Pharmaceuticals 64 Jan 19, 2016: Zogenix Receives Fast Track Designation From FDA for Development of ZX008 in Dravet Syndrome 64 Jan 11, 2016: Zogenix Announces Initiation of Phase 3 Program for ZX008 in Dravet Syndrome 64 Dec 14, 2015: Zogenix Announces FDA Acceptance of Investigational New Drug Application for ZX008 Phase 3 Clinical Trial in Dravet Syndrome 65 Dec 07, 2015: Biscayne Pharmaceuticals Presents Data At 2015 AES Meeting Confirming BIS-001 Is A Novel Mechanism, Highly Potent And Well-Tolerated Anti-Epileptic Drug 65 Dec 07, 2015: GW Pharmaceuticals Announces New Physician Reports of Epidiolex Treatment Effect in Children and Young Adults With Treatment-Resistant Epilepsy 66 Dec 07, 2015: Zogenix Announces New Efficacy and Safety Data on ZX008 for Treatment of Seizures in Dravet Syndrome 69 Appendix 71 Methodology 71 Coverage 71 Secondary Research 71 Primary Research 71 Expert Panel Validation 71 Contact Us 71 Disclaimer 72
List of Tables
Number of Products under Development for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy), H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Clinical Stage Development, H1 2016 11 Comparative Analysis by Early Stage Development, H1 2016 12 Products under Development by Companies, H1 2016 13 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by Biscayne Pharmaceuticals, Inc., H1 2016 14 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by GW Pharmaceuticals Plc, H1 2016 15 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by INSYS Therapeutics, Inc., H1 2016 16 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by OPKO Health, Inc., H1 2016 17 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by PTC Therapeutics, Inc., H1 2016 18 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by Sage Therapeutics, Inc., H1 2016 19 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by Xenon Pharmaceuticals Inc., H1 2016 20 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by Zogenix, Inc., H1 2016 21 Assessment by Monotherapy Products, H1 2016 22 Number of Products by Stage and Target, H1 2016 24 Number of Products by Stage and Mechanism of Action, H1 2016 26 Number of Products by Stage and Route of Administration, H1 2016 28 Number of Products by Stage and Molecule Type, H1 2016 30 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics - Recent Pipeline Updates, H1 2016 46 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Dormant Projects, H1 2016 60
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
